KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.

J Clin Oncol · 2025-Apr-10 · PMID 39746176

Panel Kaplan-Meier_estimates_of_PFS提取完成待 EXE 对齐验证

PFS

FIG A1. Kaplan-Meier estimates of PFS in patients with hormone receptor–positive, HER2-negative metastatic breast cancer excluding those who received AI in the adjuvant setting. AI, aromatase inhibitor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PFS, progression-free survival.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-23T17:49:43+00:00